NeuroMetrix President and Chief Executive Officer Dr. Gozani to Speak at 2016 Connected Health Conference

WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #chronicpain–NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Shai N.
Gozani, M.D., Ph.D., President and CEO of NeuroMetrix will speak on
using personal connected health for pain, addiction, and healing at the
2016 Connected
Health Conference
 to take place Monday, December 12 in Washington,
DC.

Chronic pain is estimated to impact about 20% of adults globally, and
abuse of opioid painkillers is at epidemic levels in the US. Despite $20
billion in annual out of pocket spending, over half of consumers in the
US are not satisfied with their pain relief. As a result, availability
of technology-enabled approaches to treating pain are essential. Dr.
Gozani will speak about the opportunities and challenges for connected
wearable therapeutic devices in chronic pain.

“Chronic pain goes beyond the direct pain experience to alter sleep,
activity, mood, and general health. Therefore, I was excited to see that
the Connected Health Conference is addressing chronic pain this year,”
said Dr. Gozani. “Our mission at NeuroMetrix, with the Quell®
wearable pain relief device, is to provide chronic pain sufferers with
technology that is drug-free and connected into a digital health
platform that helps them manage their pain and improve their overall
quality-of-life.”

About the Connected Health Conference

The Connected
Health Conference
, formerly the mHealth Summit, is the premier
international conference and expo for the exchange of research,
evidence, ideas, innovations and opportunities in connected health. In
its eighth year, the event features industry-leading keynote
presentations, four tracks of dynamic programming, poster presentations,
an interactive exhibit floor, pre-conference symposia and high-value
networking sessions. The Connected Health Conference is presented by the
Personal Connected Health Alliance (PCHAlliance), a non-profit
organization formed by HIMSS.

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can start, stop, and adjust therapy discreetly
via the optional Quell Relief app. Quell also offers advanced sleep
tracking that provides feedback on eight dimensions of sleep including
sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the
2016 SXSW (South by Southwest) Innovation Award for Best Wearable
Technology. Quell is available at select healthcare professionals and
retailers. Visit QuellRelief.com for
more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

Contacts

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com

?>